摘要
目的观察前列腺素E1(PGE1)序贯疗法治疗糖尿病肾损伤(DKD)的临床疗效。方法选取2010年6月至2012年6月同济大学附属第十人民医院收治的糖尿病肾损伤患者82例,将其随机分为治疗组和对照组。治疗组予PGE1序贯给药(每日2次,每次10μg,每个月7～10 d,共6个月),对照组予PGE1单疗程给药(每日2次,每次10μg,连续用药14 d)。观察两组治疗前后24 h尿蛋白等指标的变化。结果 (1)PGE1序贯治疗和单疗程给药治疗,与其治疗前基础值比较患者24 h尿蛋白定量、尿24 h微量白蛋白定量、尿NAG、尿RBP和尿β2-MG均显著降低(P<0.05);(2)随访3个月和6个月,与单疗程治疗组患者比较,序贯治疗组24 h尿蛋白定量、尿24 h微量白蛋白定量、尿NAG、尿RBP和尿β2-MG均显著降低(P<0.05),同时伴有eGFR的显著升高。结论 PGE1序贯疗法和单疗程给药均能减轻糖尿病患者肾损伤的进展;PGE1序贯疗法较单疗程给药具有更好的糖尿病肾保护作用。PGE1序贯给药安全可靠。
Objective To investigate the effect of sequential therapy of using prostaglandin El （ PGEI ） on treatment of Diabetic Kidney Disease （DKD）. Methods A prospective and randomized trial was designed for this study. All patients with DKD were randomly divided into two groups. The treatment group were administrated with PGE1 through sequential therapy （10 μg bid,7 -10 days per month,totally 6 months）. The control group received single-course PGE1 （10 μg bid, 14 days consecutively） All patients were observed between these two groups in respect of 24 h urine protein,24 h urinary albumin, NAG, β2-MG, RBP, Scr, BUN, ALB etc. Results 1 ） There was a significant decrease in both sequential therapy group and single-course group on 24 h urine protein,24 h urinary albumin, NAG, β2-MG, RBP after PGE1 treatment（ P 〈 0. 05 ）, accompanied with a large increase on eGFR. 2 ） In 3 months and 6 months of follow up ,the patients receiving sequential therapy exhibited considerably lower measured value in 24 h urine protein, 24 h urinary albumin, NAG, RBP and 132-MG as compared to that of those patients who experienced single-course PGEI treatment, （ P 〈 0. 05 ） and eGFR was also highly better improved in sequential therapy group than that of single-course group. Conclusion Not only did this study demonstrate that both sequential therapy and single-course treatment of using PGE1 would help slow down the progress of diabetic kidney diseases, also it was the first time to show that sequential therapy of PGE1 would better protect patients with DKDs from renal injury than single-course treatment using PGE1. The safety of administration of PGE1 was also guaranteed as well. All these provide promising therapy on long-term efficacy via sequential therapy of PGE1 for those patients with DKDs.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2013年第3期203-206,共4页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金资助项目(8117192
81270136)
关键词
糖尿病肾损伤
前列腺素E1
序贯疗法
尿白蛋白肌酐比值
diabetic kidney disease
prostaglandins E1
Sequential treatment
urine albumin-creatinine ratio
